RIGEL PHARMACEUTICALS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
RIGEL PHARMACEUTICALS, INC. (RIGL) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $20.24 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-04
- RIGEL PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$16.17M.
- RIGEL PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$10.96M.
- RIGEL PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$7.21M, a 145.57% decline year-over-year.
- RIGEL PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $15.83M, a 173.38% increase year-over-year.
- RIGEL PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$16.11M, a 167.23% decline from fiscal 2024.
- RIGEL PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $23.96M, a 187.74% increase from fiscal 2023.
- RIGEL PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $8.33M, a 49.52% increase from fiscal 2022.
- RIGEL PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $5.57M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $20.24M 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | -$16.17M 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | -$16.11M 10-K · filed 2026-03-03 | |||
| 2025-09-30 | -$8.15M 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | -$3.28M 10-Q · filed 2026-08-04 | |||
| 2025-03-31 | -$10.96M 10-Q · filed 2026-05-05 | |||
| 2024-12-31 | $23.96M 10-K · filed 2026-03-03 | |||
| 2024-09-30 | $18.91M 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | $3.27M 10-Q · filed 2025-08-05 | |||
| 2024-03-31 | -$7.21M 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $8.33M 10-K · filed 2026-03-03 | |||
| 2023-09-30 | $20.95M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $24.35M 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | $15.83M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $5.57M 10-K · filed 2025-03-04 | |||
| 2022-09-30 | $10.98M 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | $8.31M 10-Q · filed 2023-08-01 | |||
| 2022-03-31 | $5.79M 10-Q · filed 2023-05-02 | |||
| 2021-12-31 | -$11.48M 10-K · filed 2024-03-05 | |||
| 2021-09-30 | $30.00K 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $54.45M 10-Q · filed 2022-08-02 | |||
| 2021-03-31 | -$10.33M 10-Q · filed 2022-05-03 | |||
| 2020-12-31 | $7.85M 10-K · filed 2023-03-07 | |||
| 2020-09-30 | $14.05M 10-Q · filed 2021-11-02 | |||
| 2020-06-30 | $13.95M 10-Q · filed 2021-08-03 | |||
| 2020-03-31 | $22.70M 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | -$53.80M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | -$37.23M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | -$32.09M 10-Q · filed 2020-08-04 | |||
| 2019-03-31 | -$1.63M 10-Q · filed 2020-05-05 | |||
| 2018-12-31 | $38.03M 10-K · filed 2021-03-02 | |||
| 2018-09-30 | $23.20M 10-Q · filed 2019-11-05 | |||
| 2018-06-30 | $26.79M 10-Q · filed 2019-08-06 | |||
| 2017-12-31 | $20.66M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |